Based on the current evidence, there is no consistent association between vaccines and serious or long-term health outcomes.

Ozempic tablets are now available; investigational ALS treatment gains FDA Fast Track status; positive results for aficamten ...

HealthDay News — As an investigation continues into a hantavirus outbreak that killed three passengers and sickened five on an ocean liner, the World Health Organization (WHO) says the odds of broader ...

Treatments for COVID-19, gout, nicotine dependence, severe hypertriglyceridemia, and thyroid eye disease are under review.

Relative vaccine efficacy was 26.6 percent, which met the criteria for noninferiority, superiority, higher-level superiority.

A major amendment has prompted the FDA to extend its review of subcutaneous lecanemab as a starting dose for early Alzheimer disease.

Tazbentetol is an investigational, once-daily synaptic regenerative therapy designed to restore cognitive and motor function in ALS.

Topline data from the ACACIA-HCM study reveal that the cardiac myosin inhibitor aficamten met all primary and key secondary endpoints, offering a potential new treatment pathway for patients with ...

A larger percentage of patients in PFA group had treatment success at 12 months compared with those receiving antiarrhythmic-drug therapy.

The newly approved oral formulation features a smaller pill size in 1.5mg, 4mg, and 9mg strengths while maintaining the efficacy and safety profile of the previous oral semaglutide version.

The approval is supported by bioequivalence data assessing the once-daily extended-release formulation to twice-daily immediate-release ruxolitinib in healthy participants.

However, most patients report preferring LAI-ART administered monthly or once every 2 months vs daily oral ART.